Anna Wienner – General Manager, IBSA Hungary
Anna Wienner, general manager of IBSA Hungary, gives an update on the recent activities and achievement of the affiliate since her previous interview in 2016. Furthermore, Wienner goes on to…
Who is Janssen? We’re people; more than 35,000, working hard to treat, cure, stop and prevent some of the most devastating and complex diseases of our time — from diabetes and HIV, to Alzheimer’s and cancer.
Janssen is dedicated to addressing and solving some of the most important unmet medical needs of our time in oncology, immunology, neuroscience, infectious diseases and vaccines, and cardiovascular and metabolism. We are driven to action by the plight of patients, and we aspire to make a positive impact on their lives. That’s why we never limit the search for new medicines to our own four walls—we’re always looking to work with partners interested in helping us achieve our goals.
We stay focused on the disease areas where we believe we can make the biggest difference — oncology, neuroscience, immunology, infectious diseases & vaccines, and cardiovascular & metabolism. But success for us doesn’t stop in our labs.
The world is our lab, and we wouldn’t be able to achieve our success if it weren’t for our approach to collaboration. We work closely with like-minded people from researchers to governments, healthcare professionals to patient organizations. And we work with them at every stage, from early discovery to market access and patient education. Our experts collaborate with external parties at every stage of our value chain—from early discovery to market access. We seek medical breakthroughs wherever they occur. Whether you’re at a university, a research organization, or another biotech or pharmaceutical company, we want to hear from you.
We are Janssen. We collaborate with the world for the health of everyone in it.
Contact
Janssen-Cilag Kft.
H-1123 Budapest
Nagyenyed u. 8-14.
Tel.: + 36 1 884-2858
Fax.: + 36 1 884-2939
e-mail: janssenpharmahu@its.jnj.com
Anna Wienner, general manager of IBSA Hungary, gives an update on the recent activities and achievement of the affiliate since her previous interview in 2016. Furthermore, Wienner goes on to…
Norbert Langen, founder and CEO of Phytotec, a Hungarian distributor of evidence-based natural Rx and OTC drugs, introduces the company and its unique approach to marketing non-chemically formulated pharmaceuticals in…
Dr Ildikó Horvath, Hungary’s State Secretary for Health explains her role and shares insights on the key health trends in Hungary, the government’s top priority in improving healthcare, the importance…
Here we highlight five of the most important women working in healthcare and the life sciences in Central & Eastern Europe (CEE) today. From regulators to pharma affiliate heads with…
As the only one of Hungary’s four historical pharmaceutical manufactures to have resisted international acquisition, Gedeon Richter stands alone as the country’s national champion. However, the company does not exist…
Established in Hungary in 1913, Egis is a traditional Central Eastern European pharmaceutical company with an international footprint across the globe. As one of the four largest historical pharma companies…
Gábor Orbán, CEO of Gedeon Richter, highlights the recent turnaround of the company’s performance, its exciting new collaboration with Allergan in the US market, and the landmark launch of Gedeon’s…
Dr Péter Holchacker, director of the Hungarian Association of Innovative Pharmaceutical Manufacturers (AIPM), shares his insights on the key activities of the organisation, the collaborations it fosters with authorities and…
Attila Lukács, general manager Hungary, Romania, Bulgaria for CSL Behring outlines emergent trends in the Hungarian plasma medication market, how the affiliate has succeeded in becoming a partner to patient…
Laszlo Dinca, managing director of Vanessa Research – Hungary, shares his insights on the company’s rare and orphan disease portfolio; the intentions behind the acquisition of Hungaro-Gal Pharmaceutical Manufacturing [HG…
Irma Veberic, general manager of Roche Hungary, gives her insights on the key issues being faced by the Hungarian healthcare system and the company’s role as a partner in improving…
István Peták, co-founder and CEO of Oncompass introduces the innovative start-up and elaborates on how its solution for digital treatment planning and digital biomarkers can revolutionize not only personalized oncology…
See our Cookie Privacy Policy Here